Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
Operating Income
Iterum Therapeutics PLC
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Operating Income
-$47.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Perrigo Company PLC
NYSE:PRGO
|
Operating Income
$284.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Operating Income
$659.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Operating Income
-$137.8m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-11%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Operating Income
-$41.2m
|
CAGR 3-Years
-351%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Operating Income
€12.2m
|
CAGR 3-Years
61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
See Also
What is Iterum Therapeutics PLC's Operating Income?
Operating Income
-47.5m
USD
Based on the financial report for Dec 31, 2023, Iterum Therapeutics PLC's Operating Income amounts to -47.5m USD.
What is Iterum Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 5Y
9%
Over the last year, the Operating Income growth was -56%. The average annual Operating Income growth rates for Iterum Therapeutics PLC have been -14% over the past three years , 9% over the past five years .